

SCHEDULE

In accordance with the attached schedule instructions, you, Richard A. Gonzalez, are required to produce all records described below on behalf of AbbVie Inc.:

For the period January 1, 2009, to January 14, 2019:

1. The following documents, including communications, referring or relating to pricing or lifecycle management strategies, including but not limited to:
 - a. Whether to increase the price of Humira;
 - b. Increasing the price of Humira in response to or anticipation of changes in price of Enbrel or any other products that compete with Humira, or potential competition with Humira from other products;
 - c. The impact of any change in the price of Humira on the company's earnings, revenues, and earnings per share;
 - d. Strategies to respond to the potential loss of exclusivity for Humira or Imbruvica or to lengthen the period of exclusivity for Humira or Imbruvica; and
 - e. All communications to, from, or copying Richard Gonzalez regarding the price of Humira or Imbruvica or any strategies to increase the period of market exclusivity for Humira or Imbruvica beyond the then-existing patent expiration date or market exclusivity, and any risks posed by potential loss of exclusivity.
2. All documents, including communications, referring or relating to the potential impact on the sales, revenue, or market share of Imbruvica through the introduction of a single dosage or single tablet regimen;
3. All documents, including communications, referring or relating to the company's expenditures on drug donation or co-pay assistance programs, or any other manufacturer-affiliated or independent patient assistance or prescription assistance programs for Humira, including any analyses on the return on investment of such programs;
4. All internal and external presentations, analyses, or other documents prepared for or provided to the Board of Directors, any subcommittee of the Board of Directors, or any corporate officers, regarding pricing strategies or lifecycle management for Humira or Imbruvica;
5. Documents sufficient to show AbbVie's exact method of calculation of bonuses for the ten highest-paid employees of AbbVie Inc, between January 1, 2014, and January 14, 2019;

6. Documents sufficient to show the following information for each year from 2009 to 2019:
 - a. Cost of Goods Sold for Humira and Imbruvica;
 - b. The average net price for Humira and Imbruvica;
 - c. Highest, lowest, and average net price for Humira and Imbruvica, by channel including Medicare, Medicaid, Commercial, Veterans Affairs, and Department of Defense sales channels;
 - d. Highest, lowest, and average rebate per unit for Humira and Imbruvica, by channel including Medicare, Medicaid, Commercial, Veterans Affairs, and Department of Defense sales channels; and
 - e. AbbVie or Abbott Laboratories' yearly research and development costs related to Humira and Imbruvica.